The 52 compounds selected for the screen have been tested at 100 µM in HEK293T cells overexpressing either the β-arrestin1-RLucII (top graph) or the β2-adaptin-YFP (bottom graph) construct alone. One-way ANOVA followed by Tuckey's post-hoc tests were performed with DMSO as control to assess statistical significance of the differences (*, p<0.05; **, p<0.01; ***, p<0.001) (top graph). Compounds showing signal higher than one standard deviation from the average were identified (#) (bottom graph). Eleven of the 52 compounds were coloured (underlined below the graphs). Of these, seven had a significant effect on the luminescence and 9 affected the fluorescence signal. They were discarded from further investigation. (a) Concentration-response curves of Barbadin on V2R-induced (AVP, 100 nM) β2-adaptin/β-arrestin2 interaction assay (green line). Dotted line represents the level of AVP-promoted BRET upon pre-incubation with DMSO. Data are the mean ± S.E.M. of 3 independent experiments. (b) BRET-based assay monitoring the AVP-induced interaction between β2-adaptin-YFP and β-arrestin1-RlucII. HEK 293T cells were pre-incubated with DMSO or Barbadin (100 µM) for 30 min prior to 45 min receptor stimulation with AVP (100 nM). When indicated, cells were washed 3-times with PBS for 10 min at 37°C before agonist stimulation. Data are the mean ± S.E.M. of 3 independent experiments and one-way ANOVA followed by Tuckey's post-hoc tests were used to assess statistical significance (NS, non-significant; ***, p < 0.001). Barbadin is a specific inhibitor of the interaction between β2-adaptin and β-arrestin.
Sup. Figure S2 (Bouvier)
(a,b) BRET-based kinetics monitoring the interaction between β-arrestin2-RlucII and β2-adaptin-YFP (a) or β 2AR-YFP (b). HEK 293T cells were pretreated with DMSO or Barbadin (100 µM) for 30 min prior to receptor stimulation with ISO (10 µM) for the indicated times. Data are the mean ± S.E.M. of 3 independent experiments. (c) Cross-section confocal imaging of fixed HEK293 cells expressing β-arrestin2-mCherry and HA-V2R. Cells were serum-starved in DMEM for 30 min, and pre-treated with Barbadin (10 µM) for another 30 min before being stimulated with AVP (1µM) for 2 min then fixed, as described in the Methods section. Detection of V2R at the plasma membrane was performed using an antibody against HA (12CA5) in combination with a secondary antibody coupled to AlexaFluor488 (goat anti-mouse) in non-permeabilized, PFA-fixed, cells. Scale bar, 10 µm. To generate BRET images, the ratio of acceptor photon counts to donor photon counts was calculated for each pixel and expressed as a color-coded heat map (lowest being black and purple, and highest red and white). Scale bar, 10 µm. (a) Analysis of HEK293 cells depleted for β2-adaptin (CRISPR-β2Ad-LY5). Cells were transfected with either β 2-adaptin-CFP (β2-Ad-CFP) or pcDNA3.1 (-), and lysed 48 hours post transfection for analysis. Lysates from HEK293 and CRISPR-β2Ad-LY5 were immunoprecipitated with AP1/2 antibody, and samples analysed by Western blot using an anti-adaptin β antibody. Arrows indicate endogenous and transfected β2-adaptin.
(b,c) Visualization (b) and quantification (c) of the colocalization of either β-arrestin (βarr2) and AP2 (β2Ad) or β-arrestin and clathrin (CLC) in CRISPR-β2Ad-LY5 cells. Beta-arrestin2-mCherry and β2-adaptin-CFP, or β 2-adaptin-CFP and clathrin-YFP were transfected in HA-V2R cells. Cells were serum-starved for 30 min in the absence (DMSO) or presence of Barbadin (10 µM) and stimulated with AVP (1µM) for 2.5 min before being fixed and visualized. Colocalization of fluorescent signals is shown in top panels. Scatterplots of fluorescent signals are shown in bottom panels, and colocalization coefficients were determined from the gated signals in the scatterplots using Zen Software (Zeiss) from at least 5 cell areas from 3 different experiments. Scale bar, 2 μm. Statistical significance was assessed by one-way ANOVA, followed by a Bonferroni's multiple comparison test (*** p < 0.001).
(d) Colocalization of β-arrestin2 (βarr2-WT) and β-arrestin2 lacking its clathrin-binding site (βarr2-ΔClath) with AP2 (β2Ad). CRISPR-β2Ad-LY5 cells were transfected with either β-arrestin2-YFP (βarr2-WT -YFP) or β-arr2-Δ Clath-YFP, with β2-adaptin-mCherry and HA-V2R. Cells were serum-starved for 30 min, then incubated in the presence of 25 µM Barbadin for another 30 min before being subjected to a 2.5 min stimulation with AVP (1 µM). Cells were PBS-washed on ice and fixed before visualization. Scale bar, 2 μm.
Sup. Figure S8 (Bouvier) Supplementary Figure 8
Cells were pretreated with DMSO (a,b) or Barbadin (100 μM) (c,d) for 30 min, followed by 15 min receptor stimulation with AVP (100 nM) (b,d), prior to FACS analysis. The cell population (black + red dots) shown on the dot plots excludes cellular debris, dead cells and doublets. Non-transfected cells were used to define the threshold of the YFP-positive subpopulation (red dots), representing the HA-V2R-Venus expressing cells. Within this subpopulation, the plasma-membrane receptor localisation was monitored using the N-terminally fused HA-tag detected with an anti-Alexa647-coupled secondary antibody against an anti-HA antibody, in the absence of permeabilization. Then, the Alexa-647 mean values were expressed as a percentage of the "pretreated DMSO ; unstimulated" condition (set at 100%). 
